Phase-I trial of HSPCAR30 therapy shows 100% response and 50% remission in CD30+ lymphoma patients with no major side effects ...

In a Phase 1 clinical trial, a CAR T-cell therapy targeting the CD30 protein has been shown to promote the expansion of ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved ...

A team of Brazilian researchers has developed an innovative CAR-T cell therapy that showed positive results in patients with ...

A new Brazilian-developed CAR-T cell therapy has shown extraordinary results in treating refractory CD30+ lymphoma, including ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep ...